These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8204512)

  • 1. Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.
    Canellos GP
    Ann Oncol; 1994; 5 Suppl 2():121-2. PubMed ID: 8204512
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
    Pettengell R; Crowther D
    Ann Oncol; 1994; 5 Suppl 2():133-41. PubMed ID: 7911317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose chemotherapy with bone marrow transplantation in recurrent or refractory NHL].
    Torello E; Koziner B
    Sangre (Barc); 1993 Dec; 38(6):473-80. PubMed ID: 7909622
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Ayash LJ; Elias A; Wheeler C; Tepler I; Schwartz G; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(4):507-11. PubMed ID: 7916250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical use of hematopoietic growth factors in treatment of bone marrow failure].
    Robak T; Krykowski E
    Pol Arch Med Wewn; 1994 Jul; 92(1):1-8. PubMed ID: 7971472
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical use of hematopoietic growth factors].
    Gianni AM; Bregni M; Siena S; Tarella C; DiNicola M; Bonadonna G
    Haematologica; 1991 Jun; 76 Suppl 3():3-10. PubMed ID: 1752526
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
    Liem GS; Verweij J
    Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
    Hackshaw A; Sweetenham J; Knight A
    Br J Cancer; 2004 Apr; 90(7):1302-5. PubMed ID: 15054445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
    Chisesi T
    Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance avoided, prognosis improved--myocet in AIDS-related non-Hodgkin's lymphoma].
    Pohlmann BK
    Onkologie; 2004 Oct; 27(5):514-5. PubMed ID: 15595188
    [No Abstract]   [Full Text] [Related]  

  • 17. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
    Sweetenham JW; Johnson PW
    J Clin Oncol; 1994 Dec; 12(12):2766. PubMed ID: 7989954
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant growth factors.
    Goodnough LT; Anderson KC
    Transfus Sci; 1995 Mar; 16(1):45-62. PubMed ID: 10155704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas.
    Hansen PB; Johnsen HE; Ralfkiaer E; Jensen L; Gaarsdal E; Hansen NE
    Leuk Lymphoma; 1995 Nov; 19(5-6):453-60. PubMed ID: 8590846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
    Ganser A; Ottmann OG; Hoelzer D
    Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.